Skip to main
SIBN

SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE Inc (SIBN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

SI-BONE is poised for success in the coming years, with a strong financial outlook and multiple avenues for growth. The company's partnerships with Smith & Nephew and its continued focus on innovation suggest potential upside to its initial mid-teens growth outlook. They have a solid revenue beat in 4Q and increased both gross margins and adjusted EBITDA. Analysts expect continued growth and profitability as SIBN's technology expands into new markets, making it a solid choice for investors.

Bears say

SI-BONE is a medical device company that develops and commercializes minimally invasive surgical implants and instruments for sacroiliac joint dysfunction, adult spinal deformity and degeneration, and pelvic trauma. Despite management's efforts to drive adoption and expand partnerships, the company's revenue growth has been weak internationally and may face challenges in the US due to lower-than-expected market penetration and sluggish adoption by surgeons. Additionally, the company's bear case scenario, assuming low-teens revenue growth, corresponds to a significant decline in stock value to $15 per share, indicating overall weakness in financial performance.

SI-BONE Inc (SIBN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About SI-BONE Inc (SIBN) Forecast

Analysts have given SI-BONE Inc (SIBN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, SI-BONE Inc (SIBN) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

SI-BONE Inc (SIBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.